Published on Wed Jun 09 2021

Highly-specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA

Piano Mortari, E., Russo, C., Vinci, M. R., Terreri, S., Fernandez Salinas, A., Piccioni, L., Alteri, C., Colagrossi, l., Coltella, L., Ranno, S., Linardos, G., Agosta, M., Albano, C., Agrati, C., Castilletti, C., Meschi, S., Romania, P., Roscilli, G., Pavoni, E., Camisa, V., Santoro, A., Brugaletta, R., Magnavita, N., Ruggiero, A., Cotugno, N., Amodio, D., Cioffi Degli Atti, M. L., Giorgio, D., Russo, N., Salvatori, G., corsetti, t., Locatelli, F., Perno, C. F., Zaffina, S., Carsetti, R.

Specific memory B cells and antibodies are reliable read-out of vaccine efficacy. We analyzed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly-specific memory B Cells and antibodies.

4
0
0
Abstract

Specific memory B cells and antibodies are reliable read-out of vaccine efficacy. We analyzed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly-specific memory B cells and antibodies. Two months after the second dose, specific antibody levels decline, but highly specific memory B cells continue to increase thus predicting a sustained protection from COVID-19. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/21258284v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): [email protected]@[email protected][email protected]_HPS_FORMAT_FIGEXP M_FIG Graphical Abstract C_FIG